Feb 10 2011
· Net revenue for the fourth quarter amounted to SEK 3.5 million (5.8) and for January-December SEK 18.5 million (24.0).
· The net loss for the fourth quarter totaled SEK 7.4 million (5.4) and for January-December SEK 22.4 million (18.6).
· Earnings per stock unit for the fourth quarter amounted to SEK -0.07 (-0.09) and for January-December SEK -0.32 (-0.31).
· Artimplant's own sales as a proportion of total sales continued to increase and were equivalent to 70% (60) of product sales for the fourth quarter, equivalent to 61% (37) for the full year.
· Compared to 2009, Artimplant's own sales in the USA more than doubled whilst revenue from license sales was halved.
· Artimplant's rights issue was subscribed up to 189% and generated capital input for the Company of approximately SEK 38.5 million before issue costs.
· Artimplant's strategy has been focused on marketing with increased intensity in own sales in the USA.
· Artimplant implemented staff cutbacks in Sweden during the fall of 2010 equivalent to an annual saving of approximately SEK 5 million once the periods of notice came to an end. At the same time the Company has employed more product specialists in the USA.
· The Board proposes that no dividend be paid for 2010.
Events after the period-end
· The launch of the new Artelon® Tissue Reinforcement products has commenced.